Clinical Diagnosis and Treatment of Thrombocytopenia-Inducing Diseases

Dear Colleagues,

Thrombocytopenia represents a not infrequent finding in patients presenting to hospitals emergency services. Likewise, loss of platelets not only due to disease processes but also as a result of therapies needed to treat diseases are common in clinical settings. Indeed, etiologies that affect the bone marrow’s capacity to replenish blood elements such as malignancies that are either begin or metastasize to the marrow, and even those in which immune system dysregulation leads to antibody formation that either directly or indirectly affect platelets, can be considered as primary issues eliciting different degrees of thrombocytopenia. On the other hand, iatrogenic causes such as medications and physiologic processes such as acute bleeding, infections, and mechanical damage, as in the use of medical devices that consume or impair platelets, can equally drive thrombocytopenia. With so many new developments to address thrombocytopenias being developed that include the development of immunomodulators such as monoclonal antibody therapies, it is becoming more clear that some of these thrombocytopenia-eliciting etiologies can be better treated. Thus, the aim of this Special Issue is to become a forum to showcase novel research from basic science to clinical and translational work encompassing thrombocytopenic presentations. Original reports and reviews are welcome. Case reports or case series may be considered in the context of a thorough review of the relevant literature.

Dr. Robert W. Maitta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• thrombocytopenia
• antibody
• malignancy
• anemia
• immune dysregulation
• antibiotics
• iatrogenic